Seattle Genetics, Inc. (SGEN) news: Seattle Genetics' CEO Discusses Q4 2013 ... Seeking Alpha In this trial, 329 Hodgkin lymphoma patients at high risk of disease progression after autologous stem cell transplant were randomized to receive ADCETRIS or placebo. Based on the current rate of progression, reaching the targeted number of event, it ... |
